Jubilant Pharmova Limited has published newspaper advertisements regarding the transfer of unclaimed dividends and equity shares to the Investor Education and Protection Fund (IEPF) Authority, following its regulatory filing with stock exchanges. The company submitted copies of these newspaper advertisements to BSE Limited and National Stock Exchange of India Limited on March 31, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Newspaper Publication and Regulatory Compliance

The company published the IEPF transfer notice in Financial Express (English Language – All Editions) and Hindustan & Jansatta (Hindi language) on March 31, 2026. This publication follows the company's earlier regulatory communication submitted on March 30, 2026, ensuring comprehensive shareholder outreach across multiple languages and publications.

IEPF Transfer Requirements and Timeline

Under Section 124(6) of the Companies Act, 2013, read with the IEPF Rules 2016, companies must transfer shares to the IEPF Authority when dividends remain unclaimed for seven consecutive years or more. The company has identified shareholders with unclaimed dividends from financial year 2018-19 onwards, which are scheduled for IEPF transfer.

Critical Dates for Shareholders

Shareholder Action Required

Shareholders with unclaimed dividends must submit applications to Alankit Assignments Limited, the company's Share Transfer Agent, on or before May 15, 2026. The company has uploaded details of affected shareholders on its website at www.jubilantpharmova.com/investors/unclaimed-dividend-and-shares for verification purposes.

Contact Information for Claims

Post-Transfer Recovery Process

Once shares are transferred to IEPF, shareholders retain the right to claim both dividends and shares from the IEPF Authority by filing Form IEPF-5 and following prescribed procedures under the IEPF Rules. All subsequent corporate benefits accruing on transferred shares will also be credited to the IEPF Authority until claimed by rightful shareholders.

Company Secretary Naresh Kapoor has signed the official communications, emphasizing the urgency for shareholders to act before the May 15, 2026 deadline to avoid the transfer process.

Jubilant Pharmova has announced that its Board of Directors approved the unaudited financial results for the quarter and nine months ended December 31, 2025, at a meeting held on February 6, 2026. The pharmaceutical company has filed the consolidated and standalone financial results with stock exchanges and published them in newspapers for public access.

Board Meeting and Approval Process

The Board of Directors meeting was conducted on Friday, February 6, 2026, commencing at 10:30 A.M. and concluding at 12:35 P.M. The board approved both standalone and consolidated unaudited financial results for the third quarter and nine months period ended December 31, 2025, in accordance with Regulation 33 read with Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The Audit Committee reviewed these results at its meeting held on February 5, 2026.

Newspaper Publication and Public Access

Pursuant to Regulation 30 and Regulation 47 of the SEBI regulations, Jubilant Pharmova submitted copies of published financial results to stock exchanges on February 7, 2026. The company published Quick Response Codes and webpage details in Financial Express (English) and Jansatta & Hindustan (Hindi) newspapers dated February 7, 2026, providing investors easy access to complete financial results.

Regulatory Filings and Documentation

The company has filed comprehensive documentation with both BSE Limited and National Stock Exchange of India Limited. The filings include unaudited financial results for both standalone and consolidated operations, along with limited review reports from statutory auditors Walker Chandiok & Co LLP. The results are also accessible through stock exchange websites and the company's official website.

Upcoming Investor Engagement

Jubilant Pharmova has scheduled physical investor and analyst meetings for February 9, 2026, in Mumbai to discuss the Q3FY26 earnings performance. The meetings, organized by Nuvama Institutional Equities as part of their India Conference 2026, will include 29 institutional investors from domestic and international asset management companies.